Chimeric double-stranded nucleic acid
A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
1. A pharmaceutical composition which comprises a double stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein:
(i) the first nucleic acid strand does not comprise DNA nucleotides and hybridizes to a transcription product of a target gene to modify the expression of the target gene by a non-RNase H-dependent antisense effect, wherein the first nucleic acid strand comprises
(a) consecutive modified nucleotides, nucleotide analogs and/or modified nucleotide analogs which have a sequence complementary to the transcription product and can hybridize to the transcription product, and
(b) a 5′ wing region which comprises one or more nucleotide analogs or modified nucleotide analogs located on the 5′ terminal side of the consecutive modified nucleotides, nucleotide analogs and/or modified nucleotide analogs, and/or
(c) a 3′ wing region which comprises one or more nucleotide analogs or modified nucleotide analogs located on the 3′ terminal side of the consecutive modified nucleotides, nucleotide analogs and/or modified nucleotide analogs, and
(d) the total number of the nucleotides, modified nucleotides and nucleotide analogs is 12 to 25 nucleotides, and
(ii) the second nucleic acid strand comprises
(a) consecutive RNA nucleotides or modified RNA nucleotides which have a sequence complementary to the first nucleic acid, and
the second nucleic acid strand comprises
(b) one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located on the 5′ terminal side of the consecutive RNA nucleotides or modified RNA nucleotides, and/or
(c) one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located on the 3′ terminal side of the consecutive RNA nucleotides or modified RNA nucleotides, and
(d) the total number of the nucleotides, modified nucleotides and nucleotide analogs is 12 to 25 nucleotides.
2. The pharmaceutical composition of claim 1 , wherein the non-RNase H-dependent antisense effect is the inhibition of the translation of the transcription product or a splicing function modifying effect.
3. The pharmaceutical composition of claim 1 , wherein the non-RNase H-dependent antisense effect is exon skipping.
4. The pharmaceutical composition of claim 1 , wherein the second nucleic acid strand further comprises a functional moiety having a targeted delivery function.
5. The pharmaceutical composition of claim 4 , wherein the functional moiety is a lipid.
6. The pharmaceutical composition of claim 5 , wherein the lipid is selected from cholesterol, a fatty acid, a lipid-soluble vitamin, a glycolipid, and a glyceride.
7. The pharmaceutical composition of claim 5 , wherein the functional moiety is selected from cholesterol, a tocopherol, and a tocotrienol.
8. The pharmaceutical composition of claim 4 , wherein the functional moiety is a peptide or a protein selected from a ligand of a receptor and an antibody.
9. The pharmaceutical composition of claim 1 , wherein the second nucleic acid strand comprises:
(a) an RNA nucleotide or a modified RNA nucleotide and optionally a nucleotide analog, and optionally a DNA nucleotide; or
(b) a DNA nucleotide and/or a nucleotide analog; or
(c) PNA nucleotide.
10. The pharmaceutical composition of claim 1 , wherein the transcription product is a protein-coding mRNA transcription product.
11. The pharmaceutical composition of claim 1 , wherein the transcription product is a non-protein-coding transcription product.
12. The pharmaceutical composition of claim 1 , wherein the transcription product is a mRNA precursor that has not been spliced.
13. The pharmaceutical composition of claim 1 , wherein the total number of nucleotides, modified nucleotides, nucleotide analogs and/or modified nucleotide analogs in the first nucleic acid strand and the total number of RNA nucleotides, modified RNA nucleotides, DNA nucleotides, nucleotide analogs, and PNA nucleotides in the second nucleic acid strand are the same.
14. The pharmaceutical composition of claim 13 , wherein the total number of nucleotides, modified nucleotides and optionally comprised nucleotide analogs in the first nucleic acid strand and the total number of RNA nucleotides, modified RNA nucleotides, DNA nucleotides, nucleotide analogs, and PNA nucleotides in the second nucleic acid strand are different.
15. The pharmaceutical composition of claim 14 , wherein the total number of RNA nucleotides, modified RNA nucleotide, DNA nucleotides, nucleotide analogs, and PNA nucleotides in the second nucleic acid strand is greater than the total number of nucleotides, modified nucleotides and optionally comprised nucleotide analogs in the first nucleic acid strand.
16. The pharmaceutical composition of claim 15 , wherein the first nucleic acid strand comprises one or more nucleotide analogs located 5′ and/or 3′ to the consecutive modified nucleotides, nucleotide analogs and/or modified nucleotide analogs which have a sequence complementary to the transcription product.
17. The pharmaceutical composition of claim 16 , wherein the first nucleic acid strand comprises the 5′ wing region and the 3′ wing region, and wherein the 5′ wing region comprises at least 2 nucleotide analogs and the 3′ wing region comprises at least 2 nucleotide analogs.
18. The pharmaceutical composition of claim 17 , wherein the 5′ wing region and the 3′ wing region independently comprise 2 to 10 nucleotide analogs.
19. The pharmaceutical composition of claim 18 , wherein the 5′ wing region and the 3′ wing region independently comprise 2 to 3 nucleotide analogs.
20. The pharmaceutical composition of claim 1 , wherein the modified nucleotides of the first nucleic acid strand comprise at least one nucleotide comprising a 2′-O—CH 3 group or a 2′-O—CH 2 CH 2 OCH 3 (MOE) group.
21. The pharmaceutical composition of claim 1 , wherein the first nucleic acid strand comprises at least one nucleotide analog which is a bridged nucleotide.
22. The pharmaceutical composition of claim 21 , wherein the first nucleic acid strand comprises bridged nucleotides independently selected from LNA, cEt-BNA, amideBNA (AmNA), and cMOE-BNA.
23. The pharmaceutical composition of claim 13 , wherein the first nucleic acid strand comprises bridged nucleotides independently selected from a ribonucleotide in which the carbon atom at the 2′-position and the carbon atom at the 4′-position are bridged by 4′-(CH 2 ) p-O-2′, 4′-(CH 2 ) p-S-2′, 4′-(CH 2 ) p-OCO-2, 4′-(CH 2 ) n-N(R 3 )—O—(CH 2 ) m-2′, where p, m and n represent an integer from 1 to 4, an integer from 0 to 2, and an integer from 1 to 3, respectively, and R 3 represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an aralkyl group, an acyl group, a sulfonyl group.
24. The pharmaceutical composition of claim 13 , wherein the first nucleic acid strand comprises nucleotide analogs independently selected from PNA, GNA, TNA, tcDNA, morpholino nucleic acid, 2′-O-methylated nucleic acid, 2′-O-methoxyethylated nucleic acid, and BNA.
25. The pharmaceutical composition of claim 1 , wherein at least one of the nucleotides or modified nucleotides of the first nucleic acid strand are phosphorothioated.
26. The pharmaceutical composition of claim 1 , wherein at least one of the nucleotide analogs of the first nucleic acid strand are phosphorothioated.
27. The pharmaceutical composition of claim 13 , wherein the first nucleic acid strand comprises the 5′ wing region and the 3′ wing region, and wherein
(i) the nucleotide analogs of the 5′ wing region are bridged nucleotides;
(ii) the nucleotide analogs of the 3′ wing region are bridged nucleotides; and
(iii) the consecutive nucleotides which have a sequence complementary to the transcription product are modified nucleotides.
28. The pharmaceutical composition of claim 27 , wherein the second nucleic acid strand comprises one or more phosphorothioated nucleotides located 5′ and/or 3′ to the consecutive RNA nucleotides or modified RNA nucleotides which have a sequence complementary to the first nucleic acid strand.
29. The pharmaceutical composition of claim 28 , wherein the second nucleic acid strand comprises
a 5′ wing region consisting of one or more nucleotide analogs located 5′ to the consecutive RNA nucleotides or modified RNA nucleotides which have a sequence complementary to the first nucleic acid, and/or
a 3′ wing region consisting of one or more nucleotide analogs located 3′ to the consecutive RNA nucleotides of modified RNA nucleotides which have a sequence complementary to the first nucleic acid.
30. The pharmaceutical composition of claim 29 , wherein the second nucleic acid strand comprises the 5′ wing region and the 3′ wing region, and wherein the 5′ wing region comprises at least 2 nucleotide analogs and the 3′ wing region of the first strand comprises at least 2 nucleotide analogs.
31. The pharmaceutical composition of claim 30 , wherein the 5′ wing region and the 3′ wing region independently comprise 2 to 10 nucleotide analogs.
32. The pharmaceutical composition of claim 30 , wherein the 5′ wing region and the 3′ wing region independently comprise 2 to 3 nucleotide analogs.
33. The pharmaceutical composition of any one of claims 30 to 32 , wherein the second nucleic acid strand comprises at least one RNA nucleotide comprising a 2′-O—CH 3 group or a 2′-O—CH 2 CH 2 OCH 3 (MOE) group.
34. The pharmaceutical composition of any one of claims 30 to 32 , wherein the second nucleic acid strand comprises at least one nucleotide analog which is a bridged nucleotide.
35. The pharmaceutical composition of claim 34 , wherein the second nucleic acid strand comprises bridged nucleotides independently selected from LNA, cEt-BNA, amideBNA (AmNA), and cMOE-BNA.
36. The pharmaceutical composition of claim 34 , wherein the second nucleic acid strand comprises bridged nucleotides independently selected from a ribonucleotide in which the carbon atom at the 2′-position and the carbon atom at the 4′-position are bridged by 4′-(CH 2 ) p-O-2′, 4′-(CH 2 ) p-S-2′, 4′-(CH 2 ) p-OCO-2, 4′-(CH 2 ) n-N(R 3 )—O—(CH 2 ) m-2′, where p, m and n represent an integer from 1 to 4, an integer from 0 to 2, and an integer from 1 to 3, respectively, and R 3 represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an aralkyl group, an acyl group, a sulfonyl group.
37. A method for modifying the expression of a target gene by a non-RNase H-dependent antisense effect comprising contacting a cell with the pharmaceutical composition of claim 1 .